aTYR PHARMA INC: cash and cash equivalents
Cash and cash equivalents for aTYR PHARMA INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All aTYR PHARMA INC financial histories
What this measure means
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
Exact concept: us-gaap:CashAndCashEquivalentsAtCarryingValue. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2012-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 10,743,000 | USD | 2026-03-05 | 10-K · 0001339970-26-000008 |
| At date | 2024-12-31 | 11,055,000 | USD | 2026-03-05 | 10-K · 0001339970-26-000008 |
| At date | 2023-12-31 | 22,544,000 | USD | 2026-03-05 | 10-K · 0001339970-26-000008 |
| At date | 2022-12-31 | 9,981,000 | USD | 2025-03-13 | 10-K · 0000950170-25-038888 |
| At date | 2021-12-31 | 2,336,000 | USD | 2024-03-14 | 10-K · 0000950170-24-031584 |
| At date | 2020-12-31 | 16,952,000 | USD | 2023-03-14 | 10-K · 0000950170-23-007873 |
| At date | 2019-12-31 | 9,210,000 | USD | 2021-03-24 | 10-K · 0001564590-21-014940 |
| At date | 2018-12-31 | 22,962,000 | USD | 2020-03-26 | 10-K · 0001564590-20-013208 |
| At date | 2017-12-31 | 21,091,000 | USD | 2019-03-26 | 10-K · 0001564590-19-009381 |
| At date | 2016-12-31 | 38,388,000 | USD | 2019-03-26 | 10-K · 0001564590-19-009381 |
| At date | 2015-12-31 | 53,025,000 | USD | 2019-03-26 | 10-K · 0001564590-19-009381 |
| At date | 2014-12-31 | 13,899,000 | USD | 2018-03-20 | 10-K · 0001564590-18-006333 |
| At date | 2013-12-31 | 36,457,000 | USD | 2017-03-16 | 10-K · 0001564590-17-004631 |
| At date | 2012-12-31 | 3,675,000 | USD | 2016-03-30 | 10-K · 0001564590-16-015652 |
Related financial histories
- aTYR PHARMA INC: total assets
- aTYR PHARMA INC: stockholders equity
- aTYR PHARMA INC: net income or loss
- aTYR PHARMA INC: operating cash flow
- aTYR PHARMA INC: capital expenditure payments
- aTYR PHARMA INC: contract revenue excluding tax
- aTYR PHARMA INC: financing cash flow
- aTYR PHARMA INC: investing cash flow
- aTYR PHARMA INC: retained earnings or deficit
- aTYR PHARMA INC: basic weighted-average shares
- aTYR PHARMA INC: diluted weighted-average shares
- aTYR PHARMA INC: basic earnings per share
- aTYR PHARMA INC: diluted earnings per share
- aTYR PHARMA INC: income tax expense or benefit
- aTYR PHARMA INC: net property, plant and equipment
- aTYR PHARMA INC: operating income or loss
- aTYR PHARMA INC: current assets
- aTYR PHARMA INC: current liabilities
- aTYR PHARMA INC: current accounts payable
- aTYR PHARMA INC: operating expenses
- aTYR PHARMA INC: research and development expense
Inspect the source
- Entity
- aTYR PHARMA INC / CIK 0001339970
- Captured
- 2026-09-20T07:54:07.036Z
- SEC response SHA-256
c3475f065ea6b54c344b2c997462c8932379247c1ed7107b14d14669b6000cf2
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001339970.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))